Bristol-Myers Squibb signs exclusive worldwide license agreement with PsiOxus Therapeutics
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, "armed" oncolytic virus with the goal of addressing solid tumors. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
- Details
- Category: Novartis
Novartis announced today the signing of an exclusive option, collaboration and license agreement with Conatus Pharmaceuticals Inc., a biotechnology company focused on the development of novel medicines to treat liver disease. This agreement will enable Novartis and Conatus to jointly develop emricasan.
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
- Details
- Category: Novartis
Novartis announced today that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. This acquisition would add a once-daily oral H4 receptor antagonist in development for atopic dermatitis (AD), commonly known as eczema, to complement the growing Novartis dermatology portfolio and pipeline.
Pfizer announces expansion of ASPIRE awards program for 2017 to include $5.5M in funding for breast and hematologic cancers
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has announced that it will expand the company's Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) program in 2017 to award up to $5.5 million (USD) in new competitive grants to fund research studies involving Pfizer products in both breast and hematologic cancers. This expanded program will be known as the ASPIRE Oncology/Hematology Clinical Research Awards.
Bristol-Myers Squibb strengthens capabilities with evolution of its U.S. geographic footprint
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced important changes to its U.S. geographic footprint that will strengthen capabilities of the company's R&D hubs of world-class science and innovation in Central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts while further integrating biologics development with clinical manufacturing at key sites to foster greater speed and collaboration.
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
- Details
- Category: Novartis
Novartis has announced the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology.
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
More Pharma News ...
- Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
- Abbott seeks to terminate Alere acquisition
- NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors
- Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
- IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery
- Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant in Germany
- Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss